Imperative Care Launches CLEAR-IT Study to Set Clinical Standards for Peripheral Thromboembolism
Event summary
- Imperative Care initiated the CLEAR-IT Study on March 25, 2026, to evaluate its Symphony and Prodigy Thrombectomy Systems in treating peripheral thromboembolism.
- The study aims to enroll up to 750 patients across 50 U.S. sites to assess short- and long-term clinical performance and safety.
- CLEAR-IT is co-led by Steven Abramowitz, M.D., of MedStar Hospital, and Dr. Maya Serhal, M.D., of Massachusetts General Hospital.
The big picture
Imperative Care is leveraging its experience in stroke treatment to address gaps in clinical standards for peripheral thromboembolism. The CLEAR-IT Study represents a strategic move to solidify its position in vascular health by providing evidence-based solutions. This aligns with broader industry trends toward data-driven medical device innovation and regulatory clarity.
What we're watching
- Clinical Evidence
- Whether the CLEAR-IT Study will establish robust clinical standards for peripheral thromboembolism treatment.
- Market Adoption
- The pace at which Imperative Care can expand the use of its thrombectomy systems in real-world settings.
- Competitive Positioning
- How Imperative Care’s data will differentiate its products from competitors in the peripheral thromboembolism space.
Our editorial coverage: